L-Glutamine for Pediatric Sickle Cell Disease: Pharmacology, Mechanism of Action, Safety and Efficacy
In Vivo · 2026-11 · 40 (6) · 3253-3261
DOI: 10.21873/invivo.14475 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Eduard H Panosyan. Beteiligte Einrichtung: Division of Pediatric Hematology-Oncology, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, U.S.A.; epanosyan@lundquist.org. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Glutamine. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Hematology-Oncology, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, U.S.A.; epanosyan@lundquist.org.
- The Lundquist Institute for Biomedical Innovation, Torrance, CA, U.S.A.
Zitieren
APA
Panosyan, E. H. (2026). L-Glutamine for Pediatric Sickle Cell Disease: Pharmacology, Mechanism of Action, Safety and Efficacy. In Vivo, 40(6), 3253-3261. https://doi.org/10.21873/invivo.14475
Vancouver
Panosyan EH. L-Glutamine for Pediatric Sickle Cell Disease: Pharmacology, Mechanism of Action, Safety and Efficacy. In Vivo. 2026;40(6):3253-3261. doi:10.21873/invivo.14475
BibTeX
@article{Panosyan2026,
author = {Panosyan, Eduard H},
title = {L-Glutamine for Pediatric Sickle Cell Disease: Pharmacology, Mechanism of Action, Safety and Efficacy},
journal = {In Vivo},
year = {2026},
volume = {40},
number = {6},
pages = {3253--3261},
doi = {10.21873/invivo.14475}
}
EUVIMED